about
Insights into epigenetic regulation of microRNA-155 expression in multiple myelomaEvaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myelomaTranscriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies.Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell linesGenome-Wide DNA Copy Number Analysis of Acute Lymphoblastic Leukemia Identifies New Genetic Markers Associated with Clinical Outcome.Identification and characterization of the gene expression profiles for protein coding and non-coding RNAs of pancreatic ductal adenocarcinomas.Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development.DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma.Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma.The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.Histologic Tumor Grade and Preoperative Bilary Drainage are the Unique Independent Prognostic Factors of Survival in Pancreatic Ductal Adenocarcinoma Patients After Pancreaticoduodenectomy.Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.The cellular origin and malignant transformation of Waldenström macroglobulinemia.Genomic analysis of high-risk smoldering multiple myeloma.Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse.Genomic characterization of liver metastases from colorectal cancer patients.Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma.Prognostic impact of a novel gene expression profile classifier for the discrimination between metastatic and non-metastatic primary colorectal cancer tumors.The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma.Effects of IL-8 Up-Regulation on Cell Survival and Osteoclastogenesis in Multiple Myeloma.A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility.Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.Combined assessment of the TNM stage and BRAF mutational status at diagnosis in sporadic colorectal cancer patients.Prognostic stratification of adult primary glioblastoma multiforme patients based on their tumor gene amplification profiles.Polymorphisms in receptors involved in opsonic and non-opsonic phagocytosis and the risk of infection in oncohematological patientsSNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma statusPhenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosisPhenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potentialDetailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profileRedefining synchronous colorectal cancers based on tumor clonalityFactors Regulating microRNA Expression and Function in Multiple MyelomaThe presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximabAltered interphase fluorescence in situ hybridization profiles of chromosomes 4, 8q24, and 9q34 in pancreatic ductal adenocarcinoma are associated with a poorer patient outcomeComparing the eighth and the seventh editions of the American Joint Committee on Cancer staging system and the Brigham and Women's Hospital alternative staging system for cutaneous squamous cell carcinoma: Implications for clinical practiceFAM46C controls antibody production by the polyadenylation of immunoglobulin mRNAs and inhibits cell migration in multiple myelomaPrognostic implications of EGFR protein expression in sporadic colorectal tumors: Correlation with copy number status, mRNA levels and miRNA regulationTranscriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background
P50
Q28253748-03C3CF6A-34BF-4596-8C89-F1CCAC4A299AQ28296718-55A6E542-B966-4A6E-92C3-9F92F9ABEF01Q33978937-15C634B3-6528-4FBC-8829-83A29BDB7749Q35128148-C3CC4CD5-7B45-4B27-B431-FAF6BEAF4DDBQ35922398-29C2C498-7B1A-4113-B5DB-F282F0A5675EQ36326330-EEF4DF3D-2496-477B-902A-0D5D87A66FB7Q37353724-81FA522B-D529-4A28-B30F-1CA595E808C0Q38707040-77AF038E-F1A0-43E9-BA5D-CF1CFCCF1997Q38837705-E857C791-D2AC-4DA4-BD0F-C89553EE0574Q38839531-854EB345-2CF9-457B-8782-86D0BB933748Q38968027-E39D76D7-879A-4CFE-BA7C-56340C3458CDQ39036275-B05EC31F-5493-4DFC-BE48-5B69996BE69CQ40211335-7A35CB22-4635-488E-9D99-D8AD592E5B3FQ41473438-89B74D65-7CD4-4884-8AAA-C8215BA670A0Q41847877-5A0FF4F3-B8DA-4294-8CF1-99AAC89B8F5AQ42089762-74E81BD6-B073-4EC5-AAD6-2F1F202D433CQ42317553-FFF0DF56-6277-48DA-B945-63CD1D9DB230Q42777304-F09EF021-1821-4CE5-AD52-9A2733DB619BQ47125672-87F4D8CB-2B4D-43CE-910D-FABAD4570217Q47873839-D200C720-CC50-4676-A0F9-49E8ED0A831BQ51703229-8AFF5964-0AB4-4DFD-B14F-FC830CF6636BQ52653307-90C513F5-CC32-4215-9339-C00CCA4D6942Q53213148-D19419C3-1C31-4721-8A06-02B3CCE00E7AQ55154129-2DA7C907-B586-4513-8ECD-8801FD055480Q55513456-AB133D98-18A8-43F0-8520-7613BD73FD9DQ57055918-1B981FE0-5130-487A-A0D0-E1E1F2E601D9Q59602388-16D38649-5D04-456C-ADDE-B14A974E6ADEQ60203295-F7BEAFAB-4A13-47F6-93EF-3B21E1E324D6Q60203335-22610B8F-E211-48E2-9023-1770627CE5E4Q60203403-3E31BDA0-7258-4E80-9158-5EFB9BB1B0B0Q64043490-0E9D6C95-E9C6-42A9-9DF2-9F72BA12BDEAQ64230212-869A60CD-A055-4701-9C62-B5C470E0C3A9Q86699332-AF42707E-887B-4952-9401-DA8DBD422870Q87662374-CBB2081D-3BD3-4C2E-8B36-DCA8EAC4A3C0Q90024589-1D1471FA-E7CE-4A28-B990-0309AE7AF4C4Q90105788-2EB54409-484A-47F4-A5F1-12CFD3A7099EQ90317212-82191D92-9261-4576-928E-772231C5632FQ91361821-FEBB567D-16CB-40E9-A50A-222FE2345C85
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Luis A Corchete
@en
Luis A Corchete
@nl
type
label
Luis A Corchete
@en
Luis A Corchete
@nl
prefLabel
Luis A Corchete
@en
Luis A Corchete
@nl
P108
P108
P31
P496
0000-0003-4577-8599